Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Recruiting · NCT06700057 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patient aged 18 and over.
- Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023:
- Progressive, metastatic, castration-resistant prostate cancer,
- overexpressing prostate specific membrane antigen (PSMA)
- treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).
- Patient able to lie still for 1 hour for image acquisition.
- Patient's place of residence \< 2 hours' drive from the Institut Bergonié.
- Patient has not expressed any opposition to the use of his/her medical data for research purposes.
Exclusion criteria
- None
Where it is running
1 location listed.
- Institut Bergonie - Bordeaux, France